Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Brentuximab Vedotin Consolidation After ASCT in High-Risk Classical Hodgkin Lymphoma
NCT03057795Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2017
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by City of Hope. Started May 2017; status: active, not recruiting.
02
Drugs
nivolumabbrentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03057795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057795.